PHENOM
9.11.2022 14:01:48 CET | Business Wire | Press release
Phenom today announced that a composite organization using its Intelligence Talent Experience platform to hire, develop and retain talent achieved a 449% return on investment over three years with a payback period of less than six months — equaling more than $24M in cost savings and business benefits — according to a commissioned Total Economic Impact™ (TEI) Study conducted by Forrester Consulting on behalf of Phenom.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221109005200/en/
Phenom Intelligent Talent Experience platform delivered 449% ROI according to 2022 Total Economic Impact study (Graphic: Business Wire)
As labor and talent markets continue to waver, companies are looking for solutions to counteract the volatility with more efficient, automated hiring and retention processes, and an enhanced overall experience that differentiates them from competitors.
The TEI study uncovered that with Phenom, a composite organization representative of interviewed customers standardized and streamlined hiring and retention processes and achieved the following benefits by the third year:
- 25% decrease in time to fill (or time to hire), with 30% of that decrease attributable to Phenom. Phenom facilitated faster hiring by accelerating efforts to identify, engage, screen, and schedule interviews with candidates, and enabling the growth of more qualified candidate pools.
- 30% increase in internal hires, with 70% of that increase attributable to Phenom. Phenom improved the organization's ability to fill open positions with quality internal candidates instead of hiring talent externally, decreasing costs of new-hire onboarding, training, and time to productivity.
- 50% more efficient spending to attract talent, with 80% of that improvement attributable to Phenom. With Phenom, the organization gained insights enabling it to target spending on job boards and social media that surface high-quality candidates cost-effectively.
- 11 recruiter hours saved per week. Phenom saved the organization’s recruiters time sourcing and nurturing candidate leads, communicating with candidates, scheduling candidate interviews, and analyzing where leads are in the hiring process and who ultimately gets hired.
“[Phenom’s] artificial intelligence-enabled capabilities are a key element of how Phenom helps stakeholders execute faster and better across the talent acquisition, development and retention journey,” the Forrester study states. It also notes, “Its AI-based functionality reduces the time to fill roles, increases internal mobility, drives more productive spending to attract talent, and enhances recruiter productivity. As a result, organizations that use Phenom [Intelligent Talent Experience] are better equipped to hire, develop and retain talent.”
Additional Findings From The Forrester Consulting Total Economic Impact™ Study
To construct the study, Forrester interviewed Phenom clients, identifying the challenges they experienced previously, and the benefits, costs, risks, and outcomes they witnessed while using the platform.
Prior to implementing Phenom, the companies faced the following recruitment, employee development and retention challenges:
- Competition for talent.
- External and internal expectations for the candidate experience.
- Limited ability to build and benefit from a talent community.
- Lack of tools to support internal mobility, development and employee retention.
- Cost of vacancies.
- Manual and inefficient TA processes.
- Inadequate analytics around hiring processes, spending and outcomes.
The Forrester study determined Phenom’s platform not only assisted with these challenges, it had a direct impact on cost savings with a payback period of less than six months. Over three years, the composite organization experienced these benefits:
- $16.9M saved by decreasing time to fill a position.
- $6.7M saved by increasing internal mobility.
- $3.7M saved from more efficient spending to attract talent.
- $2.3M saved from improving recruiter productivity.
Additional benefits identified in the study:
- Improved candidate experience that elevated an organization’s brand.
- Increased satisfaction and retention of current employees.
- Reduced spending on external recruiters.
- Improved productivity around recruitment events.
What Customers Said About Phenom in the Forrester Study
“We wouldn’t be able to keep up with the competition without the functionality Phenom provides,” said a vice president of talent acquisition at an industrial equipment company. The interviewee also stated, “Now, we can make informed business decisions with data…so, Phenom’s analytics help us avoid unnecessary costs, build our budgets, and determine where to shift acquisition spending so we’re not wasting money.”
“Sourcing efforts that previously took two hours can be done in 30 minutes using the CRM, especially by using its AI,” revealed a director of talent acquisition strategy and operations at a healthcare organization.
“We now have 1.5 million people in our talent pool, which helps us a lot, especially with Phenom’s AI-driven skills and job matching,” reported a global HR systems manager at a logistics company.
“Phenom has absolutely changed where and on what we spend money, and when to attract talent,” said a senior director of talent acquisition for a transportation company.
Intelligent Talent Experience is Transformational
More than 500 global and diverse companies are already using the Phenom Intelligent Talent Experience platform to connect people, data and interactions to deliver phenomenal moments with maximum efficiency throughout the talent journey.
With Phenom:
- Candidates find and choose the right job faster.
- Employees develop their skills and evolve.
- Recruiters become wildly productive.
- Managers build stronger-performing teams.
- HR aligns employee development with company goals.
- HRIS easily integrates existing HR tech to create a holistic infrastructure.
“Hiring and retention is now the most critical conversation in the boardroom,” said Mahe Bayireddi, CEO and co-founder of Phenom. “As the margins of companies tighten, company leaders are turning to HR to identify considerable cost savings through more efficient ways to hire, develop and retain quality talent. Consolidating spend with a solution that cuts across the most critical areas of both talent acquisition and management is possible — but only by combining and delivering on three core elements: experience, intelligence and automation.”
To see the full TEI study, or to learn more about Phenom, visit: info.phenom.com/forrester-tei
About Phenom
Phenom has a purpose of helping a billion people find the right job. Through AI-powered talent experiences, employers are using Phenom to hire employees faster, develop them to their full potential, and retain them longer. The Phenom Intelligent Talent Experience platform seamlessly connects candidates, employees, recruiters, hiring managers, HR and HRIS — empowering over 500 diverse and global enterprises with innovative products including Phenom Career Site, Chatbot, CMS, CRM, AI Scheduling, Video Assessments, Campaigns, University Recruiting, Talent Marketplace, Career Pathing, Gigs, Mentoring, and Referrals.
Phenom has earned accolades including: Inc. 5000’s fastest-growing companies (3 consecutive years), Deloitte Technology's Fast 500 (4 consecutive years), Business Intelligence Group's Artificial Intelligence Excellence Awards (2021 & 2022), and a regional Timmy Award for launching and optimizing HelpOneBillion.com (2020).
Headquartered in Greater Philadelphia, Phenom also has offices in India, Israel, the Netherlands, Germany and the United Kingdom.
For more information, please visit www.phenom.com. Connect with Phenom on LinkedIn, Twitter, Facebook, YouTube and Instagram.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221109005200/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release
Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P
Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release
Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
